Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 3, 2014, Pages 272-276

  Zaidi, S T R ^a   Al Omran, S ^b   Al Aithan, A S M ^b   Al Sultan, M ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b King Abdul Aziz Hospital   (Saudi Arabia)

Author keywords

colistin; dose; gram negative bacteria; minimum inhibitory concentration; multidrug resistant

Indexed keywords

COLISTIN; FUROSEMIDE; GENTAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SOFT TISSUE INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; ACUTE KIDNEY FAILURE; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 84899456465     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12138     Document Type: Article

References (21)

1. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG,. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis, 2006; 42: 657-668.
2. Boucher HW, Talbot GH, Bradley JS, et al,. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis, 2009; 48: 1-12.
3. Falagas ME, Kasiakou SK,. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis, 2005; 40: 1333-1341.
4. Lim LM, Ly N, Anderson D, et al,. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy, 2010; 30: 1279-1291.
5. Bergen PJ, Li J, Rayner CR, Nation RL,. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2006; 50: 1953-1958.
6. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J,. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis, 2012; 74: 213-223.
7. Vicari G, Bauer SR, Neuner EA, Lam SW,. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis, 2013; 56: 398-404.
8. Yilmaz GR, Bastug AT, But A, et al,. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens. J Infect Chemother, 2013; 19: 57-62.
9. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M,. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother, 2012; 18: 872-877.
10. Falagas ME, Rafailidis PI, Ioannidou E, et al,. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents, 2010; 35: 194-199.
11. Garonzik SM, Li J, Thamlikitkul V, et al,. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother, 2011; 55: 3284-3294.
12. Garner JS, Jarvis W, Emori TG, Horan TC, Hughes JM,. CDC definitions for nosocomial infections. In:, Olmsted RN, ed. PIC Infection Control and Applied Epidemiology: Principles and Practice. St. Louis: Mosby, A1-A20, 1996.
13. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Infromational Supplement. Wayne, PA: Clinical and Labarotory Standards Institute, 2012.
14. Mavros MN, Tansarli GS, Vardakas KZ, Rafailidis PI, Karageorgopoulos DE, Falagas ME,. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression. Int J Antimicrob Agents, 2012; 40: 496-509.
15. Jacob JT, DiazGranados CA,. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis, 2013; 17: e93-e100.
16. Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE,. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis, 2012; 55: 799-806.
17. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM,. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther, 2012; 10: 917-934.
18. Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, Mehta SA,. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother, 2013; 57: 5394-5397.
19. Kontopidou F, Plachouras D, Papadomichelakis E, et al,. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect, 2011; 17: E9-E11.
20. Antoniadou A, Kontopidou F, Poulakou G, et al,. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother, 2007; 59: 786-790.
21. Turkoglu M, Dizbay M, Ciftci A, Aksakal FN, Aygencel G,. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents, 2012; 39: 142-145.